Scroll To Top
Health

Company acquires exclusive rights to HIV antibody

Company acquires exclusive rights to HIV antibody

Support The Advocate
LGBTQ+ stories are more important than ever. Join us in fighting for our future. Support our journalism.

Rockville, Md.-based Human Genome Sciences on Monday acquired exclusive rights to an antibody that could be used to slow HIV replication in the bodies of HIV-positive people, The Baltimore Sun reports. Under a licensing deal with Angenix, a California pharmaceutical company, HGS gained exclusive rights to the CCR5 mAb antibody, which prevents cellular HIV infection by jamming a key receptor on the surface of immune system cells that HIV must latch on to in order to enter the cells. A Phase I clinical trial of the antibody is planned to begin later this year.

The Advocates with Sonia BaghdadyOut / Advocate Magazine - Alan Cumming and Jake Shears

From our Sponsors

Most Popular

Latest Stories

Advocate.com Editors